07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

PharmEste, Ario Pharma deal

Ario acquired transient receptor potential A1 (TrpA1) antagonist assets previously owned by PharmEste. The assets include a series of small molecule TrpA1 antagonists, patents, know-how and data. Ario said the assets have demonstrated in vivo...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

XEN-D0501: Phase IIa started

Ario began a double-blind, placebo-controlled, crossover, U.K. Phase IIa trial to evaluate oral XEN-D0501 in about 20 patients with chronic idiopathic cough. XEN-D0501 is also in Phase IIa testing to treat and prevent cough in...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Financial News

New Science Ventures financial update

New Science Ventures , New York, N.Y.   Business: Finance   Date announced: 2014-07-16   Note: New Science Ventures is looking to raise $100 million for its third fund, according to an SEC filing. The...
23:29 , Jul 18, 2014 |  BC Extra  |  Financial News

New Science Ventures planning $100 million third fund

New Science Ventures is looking to raise $100 million for its third fund, according to an SEC filing. The firm, which declined to comment, invests in life sciences and IT companies in the U.S., Europe,...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

XEN-D0501: Phase IIa started

Ario began a double-blind, placebo-controlled, crossover, U.K. Phase IIa trial to evaluate oral XEN-D0501 for 14 days in about 22 patients. The company is also planning to start a Phase II trial of XEN-D0501 in...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Financial News

Ario completes venture financing

Ario Pharma Ltd. , Cambridge, U.K.   Business: Pulmonary   Date completed: 12/11/13   Type: Venture financing   Raised: £1.9 million ($3.1 million)   Investors: New Science Ventures; Forbion Capital Partners; Seroba Kernel Life Sciences...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Ario Pharma, Xention pulmonary news

Xention spinout Provesica Ltd. changed its name to Ario, shifted its focus to respiratory diseases and raised £1.9 million ($3.1 million) in a series A round. Ario will develop Phase I compound XEN-D0501 to treat...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

XEN-D0501: Phase I data

A double-blind, placebo-controlled, crossover Phase I trial in healthy volunteers showed that oral XEN-D0501 was well tolerated at doses of up to twice-daily 5 mg for 14 days with no serious adverse events reported. Data...
07:00 , Oct 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Transient receptor potential vanilloid 1 (TRPV1; VR1) In vitro studies identified a class of TRPV1 antagonists that could help treat...
07:00 , Jul 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Sickle cell disease; pain Transient receptor potential vanilloid 1 (TRPV1; VR1) Mouse studies suggest TRPV1 antagonists could help treat pain associated with sickle cell disease....